12/8/2011. Outline. Outline. Pharmacogenomics and rationale for the use of pharmacogenomics in the clinic
|
|
- Quentin Lyons
- 6 years ago
- Views:
Transcription
1 David A Flockhart MD, PhD 1 Outline Pharmacogenomics and rationale for the use of pharmacogenomics in the clinic Basic principals for the value of pharmacogenomics The unmet disease burden and the opportunity. Pharmacogenomic opportunities and their clinical utility in cancer, cardiovascular disease and psychiatry Avoiding pitfalls and optimizing clinician uptake Outline Pharmacogenomics and rationale for the use of pharmacogenomics in the clinic Basic principals for the value of pharmacogenomics The unmet disease burden and the opportunity. Pharmacogenomic opportunities in cancer, cardiovascular disease and psychiatry Avoiding pitfalls and optimizing clinician uptake 1
2 The Genetic Evolution One Gene, One SNP One Gene, Multiple Variants Multiple Genes, Multiple Variants Pathways, Multiple Variants All Variants in the Genome SNP Variability in The Human Genome December billion base pairs ~22,000 genes 1.7% of the genome codes for protein 3.3% of the genome is as conserved as the 1.7% that codes for protein On average 1 SNP/1.2kb million SNPs that occur at > 1% frequency ~450,000 SNPs in Multiply Conserved Regions Copy number variations exist in 5-7.5% of the germline genome Most tumor DNA sequence is identical to that of the host 4-5% of the genome is in areas with high copy number variation Genome Wide Association as a Tool for Personalized Medicine: Effect Sizes are generally low Fletcher RL, Flockhart DA,
3 Pharmacogenomic Genome-Wide Association Studies Warfarin : CYP2C9 Clopidogrel: CYP2C19 Simvastatin: SLC101 Exemestane and Anastrozole: Tamoxifen : Drugs and Their Available Pharmacogenetic Tests (As of September, most are monogenic tests) Abacavir HLA *B5701 Alcohol ADH and ALDH Interferon α Il28B Clopidogrel CYP2C19 Venlafaxine CYP2D6 Codeine and hydrocodone CYP2D6 Tamoxifen CYP2D6 Methadone CYP2B6 Vincristine CYP3A5 Tacrolimus CYP3A5 Cyclophosphamide CYP2B6 Metformin OATP3 Imatinib BCR-ABL 5-Fluorouracil DPYD-TYMS Clozapine 2 SNPs in HLA-DQB1 Irinotecan UGT1A1 Azathioprine and Mercaptopurine TPMT Warfarin CYP2C9 and VKCoR Carbamazepine HLA-B* 1502 QT-prolonging Drugs Familion Adapted from Flockhart DA et al. Clin Pharmacol Ther Jul;86(1): Many are Available But Which Tests Are Valuable? Analytical Validity Laboratory Integrity Clinical Validity Accurate biomarker prediction Clinical Utility Would it change what you do? i.e. change a drug or dose 3
4 Frequency Clinical Value of a Pharmacogenetic Test Clinical Value of a Pharmacogenetic Test 12/8/2011 Principal Factors that Influence the Clinical Value of Any Pharmacogenomic Test Is there large variance in treatment outcomes? Are alternative therapies available? What s the current predictive value? A number of cancer therapies Antidepressants Azathioprine/TPMT β-blockers Current Clinical Ability to Predict Response Principles for Valuable Pharmacogenetic Tests 1. Large variance in treatment outcomes 2. Alternative therapies are available 3. Current predictive ability is low 4. Significant clinical consequences 5. Economically viable A number of cancer therapies Antidepressants Azathioprine/TPMT β-blockers Current Clinical Ability to Predict Response Determining Whether Variability is Present: The Simple Polymorphic Distribution Activity (Phenotype) Antimode 4
5 Frequency 12/8/2011 The Value of Normit Distribution Plots: Population Distribution of CYP2C19 phenotype Flockhart et al: Clin Pharmacol Ther 1995;57: Skewed Distribution The Mean is Not the Same as the Mode Activity (Phenotype) Example of a Skewed Distribution: Heterogeneity in response to Inhaled Corticosteroids Weiss ST et al. Hum Molec Genetics 2004; 13:
6 Magnitude 12/8/2011 The Problem with Mean Response Data : Heterogeneity in Response to Medicines In Clinical Trials Benefit Large Benefit with little harm (10%) Mixed Benefit and Harm (30%). Small benefit for most. Neither harm or benefit --Nonresponders(50%) Harm Harm Without Benefit (10%) Frequency of various responses in the RCT treated population Evans B, Flockhart DA et al. (2010) Consequences of Variable Treatment Response -- The Unmet Medical Need 1. Cancer: Poor outcomes due to poor therapeutic efficacy and the development of resistance 2. Cardiovascular Disease: High morbidity and mortality due to persistent disease progression 3. Psychiatry: Inadequate treatment due to side effects, poor compliance and lack of efficacy biomarkers Consequences of Variable Treatment Response -- The Unmet Medical Need 1. Cancer: Poor outcomes due to limited therapeutic efficacy and the development of resistance 2. Cardiovascular Disease: High morbidity and mortality due to persistent disease progression 3. Psychiatry: Inability to select optimal therapy due to lack of biomarkers, and poor compliance due to adverse events 6
7 Recurrence (%) 12/8/2011 Pharmacogenomic Opportunities in Cancer Tamoxifen for Breast Cancer as an example Therapeutic ceiling in endocrine therapy Imperfect prediction of response Roadmap for prognostic tests ER, PR, HER2 Precedent for multiplex arrays Highly organized tissue collection (tumor) Multiple retrospective trials to study Variability in Tamoxifen Therapy Outcome Years Control 45% Tamoxifen for 5 years 10,386 women Absolute benefit 18% NNT = 5.1 EBCTCG: Lancet 365:1687, 2005 Existing Biomarkers of Endocrine Treatment Response For ~70% of breast cancer patients Clinical Grade and stage of tumor Menopausal status Osteoporosis Genetic Pharmacogenetic effect Cytochrome P450 enzyme: CYP2D6Ongoing studies: TCL1A, UGT2B7, ABCC2 7
8 Number of subjects Subjects 12/8/2011 A Mechanistic Basis for a Tamoxifen Biomarker: CYP2D6 Generates the Active Tamoxifen Metabolites Desta et al, J Pharmacol Exp Ther Sep;310(3): CYP2D6 Pharmacogenetics Subjects EMs UMs IMs cutoff PMs Rate of Parent Debrisoquin drug to metabolite Metabolism ratio Dahl ML et al. J Pharmacol Exp Ther Jul;274(1): Tamoxifen CYP2D6 Pharmacogenetic Testing Analytical Validity OK if sufficient variants genotyped Clinical Validity OK Clinical Utility Not Demonstrated Inconsistent Validation in Clinical Trials Inconsistent genotyping methodology, trial design, dose, indication and analysis. 8
9 % grade 4/5 neutropenia Objective response (%) 12/8/2011 PharmGKB as a Tool: Irinotecan Pathway UGT1A1 TA Repeat Genotype Altered Irinotecan Neutropenia and Activity in Colon Cancer P= /6 6/7 7/7 UGT1A1 genotype N= P= /6 6/7 7/7 UGT1A1 genotype McLeod H. et al, Irinotecan Pharmacogenomic Testing Analytical Validity OK Clinical Validity OK Clinical Utility unclear because the tests value is limited to specific dosing regimes Not in widespread use 9
10 Thiopurine Methyl Transferase Cause of Highly Variable Toxicity : Granulocytopenia with Mercaptopurines:Azathioprine and 6-Mercaptopurine Used in: Acute Lymphocytic Leukemia in Children Inflammatory Bowel Disease in Adults Homozygous mutants are 0.2% of Caucasian Populations Heterozygotes are ~ 10% Homozygous wild type is 90% Metabolism of Variability in Thiopurine Methyl Transferase From: Weinshilboum et al. JPET;222: TPMT Pharmacogenomic Testing Analytical Validity OK Clinical Validity OK Clinical Utility Variable Depending on Practice Setting 10
11 Biotech Pharmacogenomics Bevacizumab (Avastin ) Interferon and IL 28b Erlotinib and K-Ras Bevacizumab in Breast Cancer Improvement in PFS/ORR did not translate into OS benefit ORR (measurable disease) 49.2% vs. 25.2% P<0.001 Miller et al. NEJM 357:2666; 2007 GOOD NEWS=all subgroups gained benefit We need something better! BAD NEWS= our common clinical variables were unable to identify an effect group Miller et al. NEJM 357:2666;
12 Pharmacogenetic Biomarkers VEGF AA & AA genotypes in combination arm outperformed control p= mo p= mo 25.2 mo 46.5 mo Median OS Control arm=25.2 mo Combination arm=26.7 mo Combination arm AA=37.0 mo Median OS Control arm=25.2 mo Combination arm=26.7 mo Combination arm AA=46.5 mo Bevacizumab Pharmacogenomic Testing Analytical Validity OK Clinical Validity OK Clinical Utility Requires Validation in Other Trials Could a Pharmacogenomics Approach bring Avastin Back? Current Pharmacogenomic Testing in Cancer Established Tests: Evolving Tests: Imatinib (Gleevec ) and BCR-ABL Erlotinib (Tarceva) and K-Ras (somatic, monogenic) Oncotype Dx and Mammaprint Irinotecan and UGT1A1 Tamoxifen and 2D6 Bevacizumab and VEGF Vincristine and CYP3A5 Cyclophosphamide and CYP2B6 Azathioprine and TPMT 12
13 Consequences of Variable Treatment Response -- The Unmet Medical Need 1. Cancer: Poor outcomes due to limited therapeutic efficacy and the development of resistance 2. Cardiovascular Disease: High morbidity and mortality due to persistent disease progression 3. Psychiatry: Inability to select optimal therapy due to lack of biomarkers, and poor compliance due to adverse events Pharmacogenomics Opportunities in Cardiovascular Disease Clopidogrel for Coronary Thrombosis as an example A large population of patients treated Great variability in both efficacy and bleeding outcomes Samples from many large prospective trials available Available pharmacokinetic biomarkers for research Platelet aggregation testing widely available Alternative dosing a possibility An alternative drug is available: prasugrel CYP2C19 generates the active metabolite of Clopidogrel (Plavix ) Simon et al. NEJM December 23 rd,
14 CV Death, MI, or Stroke (%) 12/8/2011 Comparison of prasugrel 60 mg and clopidogrel 600 mg loading dose exposure of active metabolite by CYP2C19 genetic classification. Box represents median, 25th, and 75th percentiles and whiskers represent the most extreme values within 1.5 times interquartile range of the box. AUC, area under the concentration time curve; EM, extensive metabolizer; RM, reduced metabolizer. Eur Heart J (2009) 30 (14): Carriers of a CYP2C19 Genetic Variant Experienced More Cardiovascular Events Mega JL et al, NEJM, April, 2009 CYP2C19 Effect Significant in PCI Patient Populations Simon T et al: Clinical Pharmacology & Therapeutics (2011) 90 4,
15 Pharmacogenomics Opportunities in Cardiovascular Disease Warfarin for Deep Venous Thrombosis and Atrial Fibrillation as an example A large population of patients treated Great variability in both efficacy and bleeding outcomes Samples from many large prospective trials available International Normalized Ratio available as an existing biomarker VKORC1 Haplotype and CYP2C9 Genotype changed Warfarin Dose Primary cohort: UW (N=185); Replication cohort: Wash U (N=368). All participants were Caucasian. Rieder et al. N. Eng J. Med 2005;352: [ Pharmacogenomics Opportunities in Cardiovascular Disease :Warfarin Analytical Validity OK Clinical Validity OK Clinical Utility limited because a viable alternative (INR) is available in many, but not all practice settings. Not in widespread use. 15
16 2SNPs: 10 possible hapoltypes Haplotypes Diplotypes Ying-Hong Wang PhD, Indiana University School of Medicine Observed 1AR Haplotypes in Caucasians and African American Women (WISE study) Terra et al. Clin. Pharmacol. Ther. 71:70 (2002) Of 10 theoretical diplotypes, only 4 were present in the study population Haplotypes Diplotypes SR/SR SR/SG SR/GR SG/GR Ying-Hong Wang PhD, Indiana University School of Medicine 16
17 Diplotype Predicted Beta-blocker effect: Single SNP analysis Would Miss It. Johnson et al. Clin Pharmacol & Ther. 2003,74: Consequences of Variable Treatment Response -- The Unmet Medical Need 1. Cancer: Poor outcomes due to limited therapeutic efficacy and the development of resistance 2. Cardiovascular Disease: High morbidity and mortality due to persistent disease progression 3. Psychiatry: Inability to select optimal therapy due to lack of biomarkers, and poor compliance due to adverse events 51 17
18 Pharmacogenomic Opportunities in Psychiatry Venlafaxine for Depression as an example Blockbuster drug for a common disease Variability in efficacy and toxicity Prolonged time before efficacy is evident Need for biomarkers of treatment response Exclusive Metabolism by CYP2D6 Large prospective trials with germline DNA available Venlafaxine (VEN) Is Metabolized To O-Demethylated-Venlafaxine (ODV) By CYP2D6 CYP2D6 ODV : VEN To assess CYP2D6 status VEN + ODV Total active compound Br J Clin Pharmacol. 1996;41(2): CYP2D6 Genotype Associated with Venlafaxine Efficacy Lobello KW et al. J Clin Psychiatry 71:11, Nov
19 Promising pharmacogenomic opportunities exist in cancer, cardiovascular disease and psychiatry. How to implement? Pharmacogenomic Pitfalls to Avoid 1. Inadequate testing of genetic variation 2. Inadequate analysis of known genetic variants 3. Poorly defined biomarker phenotypes 4. Inappropriate attempts to validate associations in the wrong populations 5. Ineffective communication with the clinical community 19
20 Iterative Statistical Analyses From Discovery To Clinic Validation Normit plot: discriminates between single or multiple normal components within the population Mixture normal model: identifies number of normal components within the population Membership assignment of each subject according to the probability of belonging to each subgroup Lang Li and David A. Flockhart, 2010 Outline Pharmacogenomics and rationale for the use of pharmacogenomics in the clinic Basic principals for the value of pharmacogenomics The unmet disease burden and the opportunity. Pharmacogenomic opportunities in cancer, cardiovascular disease and psychiatry Avoiding pitfalls and optimizing clinician uptake 20
21 Optimizing Clinical Uptake 1. Simple and user-friendly informatic approaches 2. Education and raising awareness 3. Team approaches involving the whole therapeutic alliance 4. Prospective trials of pharmacogenomic-guided therapy versus standard-of-care 5. Act local, think global A Tool to Aid Clinical Implementation Optimizing Clinical Uptake 1. Simple and user-friendly informatic approaches 2. Education and raising awareness 3. Team approaches involving the whole therapeutic alliance 4. Prospective trials of pharmacogenomic-guided therapy versus standard-of-care 5. Act local, think global 21
22 Role Models for Pharmacogenetics Concorde? Nuclear Power? The Longitude Problem? 22
12/8/2011. David A Flockhart MD, PhD
David A Flockhart MD, PhD 1 1 Outline Pharmacogenomics and rationale for the use of pharmacogenomics in the clinic Basic principals for the value of pharmacogenomics The unmet disease burden and the opportunity.
More informationThe ABC s of Pharmacogenomics and Pharmacogenetics. Guillaume Pare MD, M.Sc., FRCPc Research Fellow Harvard Medical School
The ABC s of Pharmacogenomics and Pharmacogenetics Guillaume Pare MD, M.Sc., FRCPc Research Fellow Harvard Medical School Objectives Understand terms relating to pharmacogenomics and pharmacogenetics Understand
More informationThe PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting
The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting Michael Laposata, MD, PhD Fody Professor of Pathology Professor of Medicine Pathologist in Chief Vanderbilt University Hospital
More informationPharmacogenomics and Health Policy
Pharmacogenomics and Health Policy Amalia M. Issa, PhD, MPH Founding Director, Program in Personalized Medicine & Targeted Therapeutics Professor and Chair Department of Health Policy and Public Health
More informationPharmacogenomics
Pharmacogenomics http://www.pharmgkb.org/ Michelle Whirl-Carrillo, PhD Department of Genetics Pharmacogenetics Defined http://www.pharmgkb.org/ The role of genetics in drug responses. F. Vogel, 1959 CP1077369-1
More informationFarmacogenomics: meerwaarde en plaats in de Klinische Biologie
Farmacogenomics: meerwaarde en plaats in de Klinische Biologie Pieter Vermeersch*, M.D. Ph.D. & Steven Pauwels, Pharm. Laboratory Medicine, UZ Leuven * EFLM / ESPT working group on Personalized Medicine
More informationDavid C. Whitcomb, MD, PhD and Philip E. Empey, PharmD, PhD
David C. Whitcomb, MD, PhD and Philip E. Empey, PharmD, PhD Part 1 MODERN MEDICINE - FOCUSED ON GERMS Germ Theory of Disease The germ theory of disease states that some diseases are caused by microorganisms.
More informationIntroduction to Pharmacogenomics
Introduction to Pharmacogenomics Ching-Lung Cheung, PhD Assistant Professor, Department of Pharmacology and Pharmacy, Centre for Genomic Sciences, HKU Overview of the lecture Overview of the lecture Introduction
More informationFDA s Critical Path Initiative and Drug Development
FDA s Critical Path Initiative and Drug Development Duu-Gong Wu, PhD Executive Director, PharmaNet Consulting The views expressed herein are solely those of the author and do not necessarily reflect the
More informationPharmacogenomics: An Update Lead author: Beth A. Lesher, Pharm.D., BCPS
Detail-Document #210701 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2005 ~ Volume 21 ~ Number 210701 Pharmacogenomics: An Update Lead
More informationPersonalized Medicine: What does it mean and why do we want to get there?
Personalized Medicine: What does it mean and why do we want to get there? Dan M. Roden MD Assistant Vice Chancellor for Personalized Medicine Principal Investigator, BioVU Vanderbilt University Medical
More informationIntroduction to Genetics and Pharmacogenomics
Introduction to Genetics and Pharmacogenomics Ching-Lung Cheung, PhD Assistant Professor, Department of Pharmacology and Pharmacy, Centre for Genomic Sciences, HKU Survey on pharmacogenomic knowledge Survey
More informationSo, just exactly when will genetics revolutionise medicine? - Part 1
So, just exactly when will genetics revolutionise medicine? - Part 1 PRO F. M A RT IN K E N N E DY D EPA RT M ENT O F PAT H O LO GY & C A R N E Y C E N T R E FO R PH A R M ACO GEN O M IC S U N IVERSIT
More informationApplication of Pharmacogenomics in Drug Development, Regulatory Review and Clinical Practice
Application of Pharmacogenomics in Drug Development, Regulatory Review and Clinical Practice NIH Principles of Clinical Pharmacology Course Bethesda, MD December 3, 2015 Shiew-Mei Huang, PhD Deputy Director
More informationImplementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium Cathelijne H. van der Wouden, PharmD PhD Candidate U-PGx Dept. of Clinical Pharmacy
More informationNew Paradigms for Advancing Personalized Medicine
1 2 New Paradigms for Advancing Personalized Medicine 1 Panelists Moderated by: Antoinette Konski, Partner, Foley & Lardner LLP Speakers: Anita Chawla, Ph.D., Vice President, Analysis Group Ken Goldman,
More informationChapter. Scientific background
Chapter Scientific background 2 Scientific background Introduction 2.1 This chapter explains how genetic variation can affect response to medicines, and uses case studies to illustrate how information
More informationGuidance for Industry
Guidance for Industry Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationPersonalized Medicine: The Promise and the Challenge
Personalized Medicine: The Promise and the Challenge Urs A. Meyer Biozentrum of the University of Basel CH-4056 Basel, Switzerland University of Washington, Division of Hematology Institute for Stem Cell
More informationThe future is. Personalized Medicine.
The future is Personalized Medicine. What is Pharmacogenomics (PGx)? Pharmacogenomics and Personalized Medicine Patient Adherence Many commonly prescribed medications used to treat everyday ailments can
More informationIntroduction to Pharmacogenetics Competency
Introduction to Pharmacogenetics Competency Updated on 6/2015 Pre-test Question # 1 Pharmacogenetics is the study of how genetic variations affect drug response a) True b) False Pre-test Question # 2 Pharmacogenetic
More informationGuideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products
12 December 2011 EMA/CHMP/37646/2009 Committee for Medicinal Products for Human Use (CHMP) Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products
More informationPersonalized Human Genome Sequencing
Personalized Human Genome Sequencing Dr. Stefan Platz DABT, Global Head Drug Safety & Metabolism Biomedical research: strengths & limitations of non-animal alternatives 06 December 2016 The Human Genome
More informationClinical Applications in Pharmacogenomics/Genomic Medicine. Post-Course Survey
Clinical Applications in Pharmacogenomics/Genomic Medicine Post-Course Survey Note: Students will be asked questions specific to the course in which they are enrolled. This is denoted throughout by use
More informationMolecular Diagnostics. Castle Medical LLC.
Molecular Diagnostics Castle Medical LLC. What is DNA testing? Pharmacogenomics is a scientific disciple that deals with the influence of patient s genotype on drug response. Objective: to deliver the
More informationSupplementary Materials Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice
Supplementary Materials Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice Supplementary File 1 S.1.1. Re-evaluating the Translation of Pharmacogenomics Knowledge
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationGeneral background text Pharmacogenetics Dihydropyrimidine dehydrogenase (DPD)
General background text Pharmacogenetics Dihydropyrimidine dehydrogenase (DPD) Last updated: 26 October 2017 Definitions in pharmacogenetics The genotype is the hereditary information about a specific
More informationApplication of Pharmacogenomics in Drug Development, Regulatory Review and Clinical Practice NIH Principles of Clinical Pharmacology, Bethesda, MD
NIH -Principles of Clinical Pharmacology Course Bethesda, MD Application of Pharmacogenomics in Drug Development, Regulatory Review and Clinical Practice, PhD Deputy Director Office of Clinical Pharmacology
More informationObjectives. Pharmacogenomics: Future Application for individualized medicine. Human Genome Project
: Future Application for individualized medicine Suphat Subongkot, Pharm.D., BCPS, BCOP Assistant Professor Pharmacy Practice Division Faculty of Pharmaceutical Sciences Khon Kaen University, Thailand
More informationClinical Pharmacogenomics: Applications to Clinical Care
Clinical Pharmacogenomics: Applications to Clinical Care May 19, 2018 Amber L. Beitelshees, PharmD, MPH University of Maryland, Baltimore School of Medicine Objectives Describe the current state of pharmacogenomics
More informationThe role of genomics in the development of new and improved therapies
The role of genomics in the development of new and improved therapies An appreciation of the importance of genetic diversity will have a profound impact on how drugs are discovered, developed and prescribed.
More informationPharmacogenomics Relating to Drug Evaluation
Pharmacogenomics Relating to Drug Evaluation Yoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA) Recent Topics relating to PGx Tarceva (erlotinib) Approved by FDA in Nov 2004 for NSCLC Randomized, Double-Blind,
More informationPharmacogenetics in American Indian Populations
Pharmacogenetics in American Indian Populations Erica L. Woodahl, Ph.D. Associate Professor Department of Biomedical and Pharmaceutical Sciences University of Montana What is Pharmacogenomics? Responders
More informationPharmacogenomics information in SmPC
Pharmacogenomics information in SmPC SmPC training presentation Note: for full information refer to the European Commission's Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationgenotyping technologies to apply CPIC prescribing
COMMENTARIES PharmCAT: A Pharmacogenomics Clinical Annotation Tool Teri E. Klein 1 and Marylyn D. Ritchie 2,3 Implementation of genomic medicine into clinical care continues to increase in prevalence in
More informationPersonalized Medicine A new challenge for applied human pharmacology?
Personalized Medicine A new challenge for applied human pharmacology? Jochen Theis, MD FFPM InHeCon Leipzig 2 nd March 2012 Personalized Medicine: Predicting Variability in Drug Response InHeCon Jochen
More informationCE Activity Announcement
Pharmacogenomics Certificate Program ACPE Activity Number(s): 0204-0000-18-743-H04-P thru to 0204-0000-18-745-H04-P 0204-0000-18-746-H01-P and 0204-0000-18-747-H01-P 0204-0000-18-748-H04-P thru to 0204-0000-18-750-H04-P
More informationMolecular Medicine and Cardiovascular Effects of Drugs
Presented at Biometrical Analysis of Molecular Markers Heidelberg, Germany 22 November 2001 Bernhard R. Winkelmann, MD Monika Seibert-Grafe, MD Walter E. Haefeli, MD Kooperationseinheit Pharmakogenomik/Angewandte
More informationPHARMACOLOGY Vol. I - Pharmacogenomics and Pharmacogenetics - Andrew A Somogyi and Janet K Coller PHARMACOGENOMICS AND PHARMACOGENETICS
PHARMACOGENOMICS AND PHARMACOGENETICS Andrew A Somogyi and Janet K Coller Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia Keywords:
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE to modify patients' exposure to drugs based on their genomic drug-response
More informationIntegrating pharmacogenetics into national formularies: setting an international research agenda. Dr Howard L McLeod
Integrating pharmacogenetics into national formularies: setting an international research agenda Dr Howard L McLeod Professor of Medicine, Genetics, and Pharmacology Washington University, St Louis, USA
More informationInvesting in Discovery
Investing in Discovery The Impact of Basic Research and the Role of the National Institute of General Medical Sciences Jeremy M. Berg, Ph.D. Director National Institute of General Medical Sciences National
More informationEach revolutionary change in
The Art and Science of Personalized Medicine M Piquette-Miller and DM Grant If it were not for the great variability among individuals, medicine might as well be a science and not an art. Sir William Osler,
More informationIntegrating Genomics in Family Medicine
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and
More informationGuideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products
1 2 3 10 January 2014 EMA/281371/2013 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation
More informationBiomarkers emerging role, limitations and requirements (regulatory view point) K Prasad MHRA, UK / PGxWP Cardiologist (GSTT)
Biomarkers emerging role, limitations and requirements (regulatory view point) K Prasad MHRA, UK / PGxWP Cardiologist (GSTT) 1 Aspects to discuss Types of BM Predictive vs Prognostic PK vs PD Safety vs
More informationGuideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products
24 September 2015 EMA/CHMP/281371/2013 Committee for Medicinal Products for Human Use (CHMP) Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products Draft
More informationimpact on a trial design and labeling
Genotyping-impact impact on a trial design and labeling Yoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA) Benefit of Pharmacogenomics Improving benefit/risk ratio More safe, more effective Adjusting
More informationCytochrome P450 Genotype Panel
DOB: Age: Gender: Visit Number (FIN): Patient Results Client: Physician: ARUP Test Code: 2013098 Collection Date: 11/29/2016 Received in lab: 11/30/2016 Completion Date: 12/07/2016 Gene Genotype Phenotype
More informationAuthor Proof. Genelex Corporation COMPANY PROFILE
COMPANY PROFILE Genelex Corporation Howard Coleman 1,2 & Kristine Ashcraft 1 Author for correspondence 1 Genelex Corporation, 3000 First Ave., Ste. One, Seattle, WA 98121, USA Tel.: +1 800 523 6487; Fax:
More informationPharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy
Author manuscript, published in "European Journal of Clinical Pharmacology 66, 8 (2010) 755-774" DOI : 10.1007/s00228-010-0857-7 Eur J Clin Pharmacol (2010) 66:755 774 DOI 10.1007/s00228-010-0857-7 REVIEW
More informationPrecision Pharmacy: Positioning Clinical Pharmacists to Improve Patient Care through Genetically Guided Medication Selection
Precision Pharmacy: Positioning Clinical Pharmacists to Improve Patient Care through Genetically Guided Medication Selection Rebecca Pulk Fellow, Center for Pharmacy Innovation and Outcomes 1 Acknowledgements
More information1/18/2018. Segment II: Select Gene-Drug Pairs for Clinical Service Implementation. Lab Space. What do you need to set up MALDI-TOF/MS PGX assays?
Segment II: What do you need to set up MALDI-TOF/MS PGX assays? The challenges of implementing MALDI-TOF/MS PGx tests Select Gene-Drug Pairs for Clinical Service Implementation Examples: Gene CYP2D6 CYP3A5
More informationTestimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationBiomarkers: Physiological & Laboratory Markers of Drug Effect
Biomarkers: Physiological & Laboratory Markers of Drug Effect Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration February 2011 Biomarker Definition A characteristic
More informationgeneombio Technologies
PHARMACOGENOMICS SERVICES geneombio Technologies PHARMACOGENOMICS S A] CANCER GENETICS Sr. No 6 8 9 0 Test Name METHOTREXATE TOXICITY (MTHFR, RFC) AZATHIOPRINE TOXICITY (TPMT) OXALIPLATIN RESPONSE PREDICTION
More informationPS02 Biomarker Analysis. Discussant. Sue-Jane Wang, Ph.D.
PS02 Biomarker Analysis Discussant Sue-Jane Wang, Ph.D. Associate Director, Adaptive Design, Pharmacogenomics/Phrmacogenetics Office of Biostatistics, Office of Translational Sciences, CDER CDER Statistics
More informationDisclosure. Gaps in Knowledge, Competence, Performance, or Patient Outcomes 7/10/2018. Overview. Precision Medicine: Outlive Your Family History
Precision Medicine: Outlive Your Family History Disclosure I have commercial relationships with: Willard H. Dere MD FACP Professor of Internal Medicine June 21, 2018 Shareholder: Amgen, BioMarin, Eli Lilly
More informationPharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 3-2014 Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine Séverine Crettol Lausanne University,
More informationENCePP Plenary meeting 12 November
ENCePP Plenary meeting 12 November Introduction to Pharmacogenomics Presented by: Marisa Papaluca Head of Scientific Support Office European Medicines Agency An agency of the European Union Pharmacogenomics
More informationGenetic Components of Predicting Drug Adverse Reactions in the Confederated Salish & Kootenai Tribal Population
Genetic Components of Predicting Drug Adverse Reactions in the Confederated Salish & Kootenai Tribal Population Mark Pershouse PhD University of Montana Department of Biomedical and Pharmaceutical Sciences
More informationEvidence Generation for Genomic Diagnostic Test Development: A Workshop November 17, 2010 The Keck Center of the National Academies
Board on Health Sciences Policy Roundtable on Translating Genomic-Based Research for Health Evidence Generation for Genomic Diagnostic Test Development: A Workshop November 17, 2010 The Keck Center of
More informationThe Clinical Pharmacogenetics Implementation Consortium (CPIC): supporting the adoption of pharmacogenetics into the EHR
The Clinical Pharmacogenetics Implementation Consortium (CPIC): supporting the adoption of pharmacogenetics into the EHR James M. Hoffman, Pharm.D. M.S. Chief Patient Safety Officer Associate Member, Pharmaceutical
More informationPersonalized Medicine: Will There be a Right Time to Implement?
Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine? Devender S. Dhanda MS MBA, Greg F. Guzauskas
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationPrecision Medicine in Sepsis
Precision Medicine in Sepsis Jean-Daniel Chiche, MD PhD jean-daniel.chiche@aphp.fr MICU & Dept Infection, Immunity & Inflammation Hôpital Cochin & Institut Cochin, Paris-F Sepsis 2017: a litany of failed
More informationYOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING
YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING THE NEW STANDARD OF CARE WHY GENETIC TESTING? Genetic testing makes it possible to know a priori how your patients will metabolize a specific drug. It is
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: 2.04.19 Pharmacogenomic and Metabolite Markers for Patients Treated With Thiopurines 2.04.48 Genetic Testing for Warfarin Dose
More informationBiomarkers: Physiological & Laboratory Markers of Drug Effect
Biomarkers: Physiological & Laboratory Markers of Drug Effect Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration January 21, 2016 Why Are Biomarkers Important?
More informationPharmacogenetics of Drug-Induced Side Effects
Pharmacogenetics of Drug-Induced Side Effects Hui - Ching Huang Department of Pharmacy, Yuli Hospital DOH Department of Pharmacology, Tzu Chi University April 20, 2013 Brief history of HGP 1953: DNA
More informationColor Medication Response Genetic Test
Color Medication Response Genetic Test Executive Summary Pharmacogenomics 90-99% of the population has at least one actionable variant in an established PGx gene. 1 4 An estimated 64.8% of medical home
More informationBiomarkers and clinical trials. Patricia woo UCL
Biomarkers and clinical trials Patricia woo UCL Definitions Surrogate biomarker: A laboratory or physical sign that is used in therapeutic trials as a substitute for a clinically meaningful endpoint, e.g.
More informationApplication of PGx in PK at FDA: Experience and Expectations
Application of PGx in PK at FDA: Experience and Expectations EMEA-EFPIA Workshop Integrating PGx into Early Drug Development London UK 19 December 2008 Lawrence J. Lesko, Ph.D., F.C.P. Office of Clinical
More informationReimbursement Strategy for Companion Diagnostics:
Reimbursement Strategy for Companion Diagnostics: Emerging Models and Requirements Edward E. Berger, Ph.D. Larchmont Strategic Advisors Definition Companion diagnostic A diagnostic test used to predict
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informatione-pkgene: A knowledge-based research tool for analysing the impact of genetics on drug exposure
GENOME DATABASES e-pkgene: A knowledge-based research tool for analysing the impact of genetics on drug exposure Houda Hachad, 1 Casey Lynnette Overby, 2 Sophie Argon, 1 Catherine K. Yeung, 1 Isabelle
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationGenomic Medicine for the University of Vermont Health Network
Genomic Medicine for the University of Vermont Health Network The heart and science of medicine. Debra G.B. Leonard, M.D., Ph.D. Chair & Professor, Pathology & Laboratory Medicine Robert Larner, M.D. College
More informationPHARMACOGENOMICS AND PERSONALISED MEDICATION THERAPY: AN OVERVIEW
83 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 4(5): September-October 2015 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND
More informationPharmacogenomics in Pain Management
WHITE PAPER Pharmacogenomics in Pain Management Personalized Pain Therapy Authors: ANDREW PURCHASE, BSc Associate Director, Safety & Risk Management PRA Health Sciences LYNN WEBSTER, MD Vice President,
More informationPersonalized Medicine: Elusive Dream or Imminent Reality?
nature publishing group STATE Personalized Medicine: Elusive Dream or Imminent Reality? LJ Lesko 1 The market for molecular diagnostic tests is predicted to grow at extraordinary rates over the next 10
More informationBackground Paper 7.4 Pharmacogenetics and Stratified Medicine
Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Update on 2004 Background Paper Background Paper 7.4 Pharmacogenetics and Stratified Medicine By Susanne J.H. Vijverberg,
More informationPharmacogenomics and adverse drug reactions in diagnostic and clinical practice 1)
Article in press - uncorrected proof Clin Chem Lab Med 2007;45(7):801 814 2007 by Walter de Gruyter Berlin New York. DOI 10.1510/CCLM.2007.184 2007/180 Review Pharmacogenomics and adverse drug reactions
More informationPharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001
Pharmacogenetics: A SNPshot of the Future Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 1 I. What is pharmacogenetics? It is the study of how genetic variation affects drug response
More informationComparative Effectiveness Research and Personalized Medicine: Policy, Science and Business. Setting the Stage. October 28, 2009 Washington, DC
Comparative Effectiveness Research and Personalized Medicine: Policy, Science and Business Setting the Stage October 28, 2009 Washington, DC Clifford Goodman, PhD Vice President clifford.goodman@lewin.com
More informationGuideline on good pharmacogenomic practice
22 February 2018 EMA/CHMP/718998/2016 Committee for Medicinal Products for Human Use (CHMP) Agreed by Pharmacogenomics Working Party 21 March 2016 Adopted by CHMP for release for consultation 28 April
More informationRESPONSE TO RFP - Title Page
University of Pennsylvania RESPONSE TO RFP - Title Page Request for Proposal (RFP) Number: 002 Issue Date: July 16, 2008 Proposal Due Date: August 18 2008 Title of RFP: Central Laboratory for a Randomized
More informationINSTRUCTIONAL DESIGN AND ASSESSMENT Development and Evaluation of a Pharmacogenomics Educational Program for Pharmacists
INSTRUCTIONAL DESIGN AND ASSESSMENT Development and Evaluation of a Pharmacogenomics Educational Program for Pharmacists Christine M. Formea, PharmD, a Wayne T. Nicholson, MD, PharmD, b Kristen B. McCullough,
More informationTranslational Medicine in the Era of Big Data: Hype or Real?
Translational Medicine in the Era of Big Data: Hype or Real? AAHCI MENA Regional Conference September 27, 2018 AKL FAHED, MD, MPH @aklfahed Disclosures None 2 Outline The Promise of Big Data Genomics Polygenic
More informationProf. Dr. Konstantin Strauch
Genetic Epidemiology and Personalized Medicine Prof. Dr. Konstantin Strauch IBE - Lehrstuhl für Genetische Epidemiologie Ludwig-Maximilians-Universität Institut für Genetische Epidemiologie Helmholtz-Zentrum
More informationMolecular Diagnostics: Market Segmentation and Opportunities
Molecular Diagnostics: Market Segmentation and Opportunities October 2010 This market report is published by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any form
More informationFrumkin, 2e Part 1: Methods and Paradigms. Chapter 6: Genetics and Environmental Health
Frumkin, 2e Part 1: Methods and Paradigms Chapter 6: Genetics and Environmental Health Genetics Genetics, the study of individual genes, has expanded to include genomics, which is the study of all the
More informationBiomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D in the UK and EU region
Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D in the UK and EU region Dr. Christian Rohlff Oxford Genome Sciences Biomarkers in Clinical Development: Implications
More informationICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3
European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE
More informationIntroduction to Pharmacogenomics in Pharmacy Practice
Pharmacy Technician Education for Association Members By: Brad Tice PharmD, MBA, FAPhA Brad Tice received his bachelor of science in pharmacy from the University of Kansas in 1994 and his doctor of pharmacy
More informationClinical application of pharmacogenomics
Clinical application of pharmacogenomics Ching-Lung Cheung, PhD Assistant Professor, Department of Pharmacology and Pharmacy, Centre for Genomic Sciences, HKU Survey on pharmacogenomic knowledge Survey
More informationGENERAL PAYER CONSIDERATIONS FOR NEW HEALTH TECHNOLOGIES (INCLUDING DIAGNOSTICS)
FORUM Payer perspectives and actions impacting diagnostics in the US and Europe Eric Faulkner, MPH Director, Quintiles Global Market Access Consulting; Executive Director, Genomics Biotech Emerging Medical
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_statin_induced_myopathy 01/01/2019 N/A 01/01/2020 01/01/2019 Description of Procedure
More informationUse of PBPK in Drug Development and Application to the Pediatric Setting
Use of PBPK in Drug Development and Application to the Pediatric Setting Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A Role for Physiologically-Based PK?
More information